MoonLake Immunotherapeutics reported a net loss of $40.56 million for the first quarter of 2025, compared to a net loss of $13.98 million in the same period last year. The increase in loss was primarily driven by higher research and development and general and administrative expenses as the company advances its clinical programs. The company ended the quarter with a strong cash position of $480.1 million and secured a non-dilutive debt facility of up to $500 million, extending its cash runway into 2028.

MoonLake Immunotherapeutics reported a net loss of $46.39 million for Q4 2024, with research and development expenses increasing to $40.36 million and general and administrative expenses rising to $9.22 million. The company maintained a strong cash position of $448.0 million, providing a runway until at least the end of 2026.

MoonLake Immunotherapeutics announced its financial results for the second quarter of 2023, highlighting significant progress with the clinical development of sonelokimab, which is currently being investigated in Phase 2 clinical trials for moderate-to-severe hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA).